Affordable Access

Access to the full text

Hydralazine and Enzalutamide: Synergistic Partners against Prostate Cancer

Authors
  • lopes, nair
  • pacheco, mariana brütt
  • soares-fernandes, diana
  • correia, margareta p.
  • camilo, vânia
  • henrique, rui
  • jerónimo, carmen
Publication Date
Aug 07, 2021
Identifiers
DOI: 10.3390/biomedicines9080976
OAI: oai:mdpi.com:/2227-9059/9/8/976/
Source
MDPI
Keywords
Language
English
License
Green
External links

Abstract

Advanced prostate cancers frequently develop resistance to androgen-deprivation therapy with serious implications for patient survival. Considering their importance in this type of neoplasia, epigenetic modifications have drawn attention as alternative treatment strategies. The aim of this study was to assess the antitumoral effects of the combination of hydralazine, a DNA methylation inhibitor, with enzalutamide, an antagonist of the androgen receptor, in prostate cancer cell lines. Several biological parameters, such as cell viability, proliferation, DNA damage, and apoptosis, as well as clonogenic and invasive potential, were evaluated. The individual treatments with hydralazine and enzalutamide exerted growth-inhibitory effects in prostate cancer cells and their combined treatment displayed synergistic effects. The combination of these two drugs was very effective in decreasing malignant features of prostate cancer and may become an alternative therapeutic option for prostate cancer patient management.

Report this publication

Statistics

Seen <100 times